Bristol-Myers Squibb Company (BMY)

Stock performance snapshot Bristol-Myers Squibb (BMY) has drawn fresh attention after a solid year-to-date total return of about 9.5%, alongside a 1-year total return near 30.8% and a current share price around US$58.54. See our latest analysis for Bristol-Myers Squibb.

BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.

Stock futures edge higher ahead of Nvidia earnings; watch Intel’s 18A push, Bristol-Myers’ Claude AI rollout, and Lowe’s outlook.

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings? ... Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain.

Bristol-Myers Squibb (BMY) opened 2026 with Q1 revenue of US$11.5b, basic EPS of US$1.31 and net income of US$2.7b, setting the tone for how investors will judge its recent profitability. The company has seen quarterly revenue move from US$11.2b and basic EPS of US$1.21 in Q1 2025 to US$11.5b ...